Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
Primary Purpose
Acute Myeloid Leukemia
Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
NILOTINIB
EVEROLIMUS
Sponsored by
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring patients with c-kit+ AML
Eligibility Criteria
Inclusion criteria:
Patients with:
- De novo AML or secondary AML from MDS who are not candidates for myelosuppressive chemotherapy, or
- De novo AML or secondary AML from MDS who have relapsed disease or are refractory to standard therapy
- Patients at least 18 years or older
- Patients with WHO performance status of 0 to 2 with a life expectancy under treatment of at least 3 months
- Patients must have recovered from prior cytotoxic chemotherapy; treatment with Hydroxyurea or Ara-C is allowed until 24 hours to first administration of study drug.
- Patients must have a serum creatinine of <= 1.5 x ULN, SGOT/SGPT <= 3 x ULN and total bilirubin <= 2.0 x ULN
- Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- Written informed consent obtained according to local guidelines
Exclusion criteria:
- Patients with AML FAB M3.
- Patients with an expected doubling of the peripheral blast within one week.
- Patients who had prior allogeneic, syngeneic, or autologous bone marrow transplant or stem cell transplant less than 2 months previously.
Impaired cardiac function, including any one of the following:
- LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by MUGA scan or echocardiogram
- Complete left bundle branch block
- Use of a cardiac pacemaker
- ST depression of > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads
- Congenital long QT syndrome dose levels of 400 to 1200 mg QD. Many of the common adverse events reported in the imatinib Phase II leukemia (STI0106, STI0110) studies were also reported in the nilotinib Phase I study, although a notably lower frequency of peripheral edema was identified in the nilotinib study.
- History of or presence of significant ventricular or atrial tachyarrhythmias
- Clinically significant resting bradycardia (< 50 beats per minute)
- QTc > 450 msec on screening ECG (using the QTcF formula)
- QT prolonging concomitant medication
- Right bundle branch block plus left anterior hemiblock, bifascicular block
- Myocardial infarction within 12 months prior to starting Nilotinib
- Unstable angina diagnosed or treated during the past 12 months
- Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- Female patients who are pregnant or breast feeding, or adults of childbearing age not employing an effective method of birth control.
- Concurrent severe and/or uncontrolled medical or psychiatric condition which may interfere with the completion of the study.
- Patients who had more than 2 prior regimens for their current relapsed or current primary refractory disease
- Patients with uncontrolled active infection.
- Patient with any pulmonary infiltrate on the baseline chest X-ray known to be new in the previous 4 weeks. Prior treatment with any investigational drug within the preceding 4 weeks
- Chronic treatment with systemic steroids or another immunosuppressive agent
- Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
- Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
- Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration)
- A known history of HIV seropositivity
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)
- Hypokalemia
- Women who are pregnant or breast feeding, or women able to conceive and unwilling to practice an highly effective method of birth control.
- Patients who have received prior treatment with an mTor inhibitor.
- History of noncompliance to medical regimens
- Patients unwilling to or unable to comply with the protocol
Sites / Locations
- Medical faculty of the Technical University Munich
Outcomes
Primary Outcome Measures
To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study
Secondary Outcome Measures
To determine the duration of hematological response. To evaluate overall survival. To evaluate the safety profile of a combination treatment of Nilotinib and RAD001. • To evaluate improvement of symptomatic parameters. • To assess mTor, cKit a
Full Information
NCT ID
NCT00762632
First Posted
September 29, 2008
Last Updated
August 7, 2012
Sponsor
Technical University of Munich
1. Study Identification
Unique Protocol Identification Number
NCT00762632
Brief Title
Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
Official Title
An Open-label Phase I/II (Proof of Concept) Trial of an Combination of Nilotinib (AMN 107) and RAD001 in Patients With Acute Myeloid Leukemia
Study Type
Interventional
2. Study Status
Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
December 2007 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Technical University of Munich
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a nonrandomized, open-label study to evaluate the efficacy and safety of combination treatment of Nilotinib and RAD001 in the treatment of c-kit + AML. Patients refractory to standard chemotherapy or not eligible to standard chemotherapy can be included. Patients will be treated with 400 mg Nilotinib bid (total daily dose 800 mg). RAD001 will be added after a treatment duration of 1 week in a dosage of 2,5 mg/day. Treatment duration will be 25 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Myeloid Leukemia
Keywords
patients with c-kit+ AML
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
NILOTINIB
Intervention Description
400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
Intervention Type
Drug
Intervention Name(s)
EVEROLIMUS
Intervention Description
Everolimus at 2,5 mg/day should be continued 25 weeks.
Primary Outcome Measure Information:
Title
To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study
Time Frame
four years
Secondary Outcome Measure Information:
Title
To determine the duration of hematological response. To evaluate overall survival. To evaluate the safety profile of a combination treatment of Nilotinib and RAD001. • To evaluate improvement of symptomatic parameters. • To assess mTor, cKit a
Time Frame
four years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patients with:
De novo AML or secondary AML from MDS who are not candidates for myelosuppressive chemotherapy, or
De novo AML or secondary AML from MDS who have relapsed disease or are refractory to standard therapy
Patients at least 18 years or older
Patients with WHO performance status of 0 to 2 with a life expectancy under treatment of at least 3 months
Patients must have recovered from prior cytotoxic chemotherapy; treatment with Hydroxyurea or Ara-C is allowed until 24 hours to first administration of study drug.
Patients must have a serum creatinine of <= 1.5 x ULN, SGOT/SGPT <= 3 x ULN and total bilirubin <= 2.0 x ULN
Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
Written informed consent obtained according to local guidelines
Exclusion criteria:
Patients with AML FAB M3.
Patients with an expected doubling of the peripheral blast within one week.
Patients who had prior allogeneic, syngeneic, or autologous bone marrow transplant or stem cell transplant less than 2 months previously.
Impaired cardiac function, including any one of the following:
LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by MUGA scan or echocardiogram
Complete left bundle branch block
Use of a cardiac pacemaker
ST depression of > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads
Congenital long QT syndrome dose levels of 400 to 1200 mg QD. Many of the common adverse events reported in the imatinib Phase II leukemia (STI0106, STI0110) studies were also reported in the nilotinib Phase I study, although a notably lower frequency of peripheral edema was identified in the nilotinib study.
History of or presence of significant ventricular or atrial tachyarrhythmias
Clinically significant resting bradycardia (< 50 beats per minute)
QTc > 450 msec on screening ECG (using the QTcF formula)
QT prolonging concomitant medication
Right bundle branch block plus left anterior hemiblock, bifascicular block
Myocardial infarction within 12 months prior to starting Nilotinib
Unstable angina diagnosed or treated during the past 12 months
Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Female patients who are pregnant or breast feeding, or adults of childbearing age not employing an effective method of birth control.
Concurrent severe and/or uncontrolled medical or psychiatric condition which may interfere with the completion of the study.
Patients who had more than 2 prior regimens for their current relapsed or current primary refractory disease
Patients with uncontrolled active infection.
Patient with any pulmonary infiltrate on the baseline chest X-ray known to be new in the previous 4 weeks. Prior treatment with any investigational drug within the preceding 4 weeks
Chronic treatment with systemic steroids or another immunosuppressive agent
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration)
A known history of HIV seropositivity
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)
Hypokalemia
Women who are pregnant or breast feeding, or women able to conceive and unwilling to practice an highly effective method of birth control.
Patients who have received prior treatment with an mTor inhibitor.
History of noncompliance to medical regimens
Patients unwilling to or unable to comply with the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Justus Prof. Duyster, MD
Organizational Affiliation
Medical faculty of the Technical University Munich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical faculty of the Technical University Munich
City
Munich
State/Province
Bavaria
ZIP/Postal Code
81675
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
We'll reach out to this number within 24 hrs